



26 October 2020

Novartis Pharma AG
Basel, Switzerland
CH-4002

Reference: EudraCT 2019-001820-36 Novartis Protocol ID CAMG334AES01.

A 12-month prospective, phase IIIb, multicenter, open-label clinical trial to assess health-related quality of life (HRQoL) in patients with chronic or high-frequency episodic migraine treated with erenumab who present associated comorbidities.

Trial 2019-001820-36 was cancelled with no patient enrollment and as such, no results will be reported.